The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
The APPLE trial began recruitment in November 2017 and ended in February 2020 (5). It was a randomised, open-label, non-comparative, multicentre, phase II study which enrolled treatment naïve patients ...
The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...
Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” The bispecific ...
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly for those with actionable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback